Association between tumor genomic mutations and the risk of PD-1 inhibitor-induced hypophysitis: a retrospective cohort study

• by Yuanyuan Zheng, Yizhen Chen, Wei Lin, Le Min

• June 8, 2026

Troponin Screening and Major Cardiovascular Adverse Events During Immune Checkpoint Inhibitor Therapy

• by Imen Hamdi, Nathan El Bèze, Soledad Henriquez, Marie-Liesse Joulia, Raphaël Colle, Delphine Loirat, Nicolas Girard, Agnès Lillo Le Louet, Christophe Caussin, Mariana Mirabel

• July 21, 2026

An FDG-first functional imaging approach in phaeochromocytoma and paraganglioma

• by Norah Alhazzaa, Mohammad M. R. Eddama, Fawziah Alorfi, Teng Teng Chung, Helen Simpson, Srirangalingam Umasuthan, Steve Hurel, Virginia Rozalen-Garcia, Tom Kurzawinski, Simon Wan, Jamshed Bomanji, Mark Gaze, Tarek Ezzat Abdel-Aziz

• July 21, 2026

The Power List 2026 is Live

We celebrate 60 inspiring individuals helping turn pharma’s boldest ideas into reality

• July 21, 2026

• 1 min